Compare REX AI Equity Premium Income ETF (AIPI) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs AstraZeneca plc — how do they compare? REX AI Equity Premium Income ETF trades at $37.42, while AstraZeneca plc trades at $158.4 (market cap $248.14B). The key difference: AstraZeneca plc pays a 2.01% dividend while REX AI Equity Premium Income ETF pays none, and REX AI Equity Premium Income ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AIPI | AZN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $209.48 |
52-Week Low | $32.45 | $147.06 |
Market Cap | — | $248.14B |
Enterprise Value | — | $275.41B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.45, up 0.29% with a bullish technical signal from moving averages, though oscillators indicate overbought conditions. The ETF maintains an aggressive weekly dividend distribution strategy yielding approximately 35% annually, supported by its AI-focused equity premium income structure. Recent news highlights the fund's transition to weekly distributions and questions about sustainability of high yields.
The high-yield strategy presents income opportunities but faces structural risks including potential NAV erosion if AI market momentum falters. Analyst sentiment remains cautious due to the capped upside from option-writing strategies and dependency on sustained technology sector performance for distribution sustainability.
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
